GlycoMimetics is now Crescent Biopharma.

For more information, please visit us at crescentbiopharma.com.

  • Skip to main content
  • Skip to footer
  • 240.243.1201
  • info@glycomimetics.com
  • Careers
  • Contact Us
Glycomimetics
  • About Us
    • About Us
    • Management Team
    • Board of Directors
    • Core Values
  • Patients
    • Clinical Trials
  • Pipeline
    • Pipeline Overview
    • Uproleselan
    • GMI-1687
    • Galectin Antagonists
    • AML & E-selectin
    • Understanding Glycobiology
  • Science
    • Scientific Publications
    • Intellectual Property
    • Platform & Research
  • Collaborations
  • Investors
    • Investors
    • Press Releases
    • Corporate Presentation
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
  • Careers
  • Contact Us
  • Search
Mechanism of Action screenshot: Binding to e-Selectins

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases.

Mechanism of Action screenshot

Our lead candidate, uproleselan, is in pivotal Phase 3 development for relapsed / refractory acute myeloid leukemia (AML) and in a Phase 2/3 trial in newly diagnosed AML patients fit for chemotherapy.

Mechanism of Action screenshot

Uproleselan has received Breakthrough Therapy and Fast Track designations from the U.S. FDA for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is an investigational first-in-class, E-selectin antagonist.

 

Mechanism of Action screenshot
GlycoMimetics is a pioneer in glycobiology applying our proprietary chemistry platform and deep understanding of the role that carbohydrates play in cell recognition to discover innovative medicines that aim to improve outcomes for patients.

News

June 5, 2025
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

November 6, 2024
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

October 29, 2024
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Events

There are currently no upcoming events.

Partnering

Collaborations are vital to the success of our business.

To drive our proprietary programs forward, we have developed significant alliances with leading academics, governmental organizations and pharmaceutical/ biotechnology companies.

Learn More

Footer

Questions?

Contact GlycoMimetics Today

Get in Touch

© GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans

Site Map | Terms of Use | Privacy | Contact Us